407 Participants Needed

FARAPULSE Ablation for Atrial Fibrillation

(ReMATCH Trial)

AA
KA
EF
KM
Overseen ByKristin Mathson
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The ReMATCH Study is a prospective, single arm, open label, multi-center, study utilizing the FARAPULSE PFA System, including the FARAWAVE and FARAPOINT PFA Catheters.

Who Is on the Research Team?

MM

Moussa Mansour,, MD

Principal Investigator

Massachusetts General Hospital

Are You a Good Fit for This Trial?

This trial is for people who've had one atrial fibrillation ablation within the last 5 years and have persistent AF, documented by a monitoring device, that doesn't stop after 7 days or needs cardioversion. Participants must be able to give informed consent and commit to all follow-up tests at an approved center.

Inclusion Criteria

I have had persistent atrial fibrillation recorded within the last 6 months.
I am willing and able to attend all follow-up visits for this study.
I had one AF ablation procedure within the last 5 years.
See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo repeat ablation of persistent atrial fibrillation using the FARAPULSE PFA System

1 day
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

8 weeks
Multiple visits (in-person)

What Are the Treatments Tested in This Trial?

Interventions

  • FARAPULSE Pulsed Field Ablation System
Trial Overview The ReMATCH Study is testing the FARAPULSE Pulsed Field Ablation System, including specific catheters designed for this procedure. It's a prospective study where all participants receive the same treatment without comparison groups.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: Single Arm ProspectiveExperimental Treatment1 Intervention
Repeat Ablation of Persistent Atrial Fibrillation, including Mitral Isthmus Catheter Ablation, with the FARAPULSE Pulsed Field Ablation System.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Boston Scientific Corporation

Lead Sponsor

Trials
758
Recruited
867,000+
Michael F. Mahoney profile image

Michael F. Mahoney

Boston Scientific Corporation

Chief Executive Officer since 2016

MBA from Wake Forest University, BBA in Finance from the University of Iowa

Kenneth Stein profile image

Kenneth Stein

Boston Scientific Corporation

Chief Medical Officer since 2020

MD from Harvard Medical School, MMSc in Clinical Investigation from Harvard-MIT Division of Health Sciences and Technology

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security